SCHEMBL697221

SCHEMBL697221

COC(=O)CCC1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
TSHR P16473 2/20 0.50
MAPT P10636 1/20 0.50
ATM Q13315 1/20 0.50
KLK7 P49862 3/20 0.49
EPHX2 P34913 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
HSD17B10 Q99714 1/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907816 0.98 HPGD (0.53) ALDH1A1HPGDMEN1KMT2ATSHR
SCHEMBL9130829 0.98 HPGD (0.53) ALDH1A1HPGDMEN1KMT2ATSHR
SCHEMBL697966 0.96 TSHR (0.50) ALDH1A1HPGDMEN1KMT2ATSHR
SCHEMBL698490 0.91
Hydrochloric Acid SCHEMBL14167163 0.89 TSHR (0.52) ALDH1A1HPGDMEN1KMT2ATSHR
SCHEMBL8885696 0.88 TSHR (0.54) ALDH1A1HPGDTSHREPHX2
SCHEMBL3904358 0.86 TSHR (0.52) ALDH1A1KMT2ATSHREPHX2
SCHEMBL28858299 0.86 ALDH1A1 (0.46) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL560936 0.86 EPHX2 (0.53) ALDH1A1HPGDTSHREPHX2
SCHEMBL13546168 0.84 EPHX2 (0.53) ALDH1A1MEN1KMT2ATSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014141181-A1 PROCESS FOR PREPARING PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LIMITED (GB) 2014-09-18 WO claimed
EP-2423199-A1 Substituted imidazoles and their use as pesticides Pfizer Limited (GB) 2012-02-29 EP claimed
EP-1981853-B1 SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES PFIZER LTD (GB) 2011-04-13 EP claimed
US-20090312326-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2009-12-17 US claimed
US-7547718-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-06-16 US claimed
US-7544706-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-06-09 US claimed
EP-1981853-A1 SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES Pfizer Limited (GB) 2008-10-22 EP claimed
US-20080125473-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-29 US claimed
US-20080119536-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-22 US claimed
WO-2007083207-A1 SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES PFIZER LIMITED (GB) 2007-07-26 WO claimed
US-20070167506-A1 SUBSTITUTED IMIDAZOLES PFIZER INC. (US) 2007-07-19 US claimed
CN-119306753-A Methods for preparing JAK inhibitors and related intermediate compounds 因西特控股公司 2025-01-14 CN disclosed
CN-108395433-B Methods for preparing JAK inhibitors and related intermediate compounds 因西特控股公司 2024-10-22 CN disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
WO-2023125373-A1 METHOD FOR PREPARING RUXOLITINIB AND INTERMEDIATE THEREOF 江苏威凯尔医药科技有限公司 2023-07-06 WO disclosed
WO-2004056751-A1 ANTIBACTERIAL AGENTS VERNALIS OXFORD LTD (GB) 2004-07-08 WO disclosed
WO-2003103604-A2 GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) 2003-12-18 WO disclosed
EP-0563705-A2 Cycloalkyl- and heterocyclyl substituted imidazolylpropenic acid derivatives BAYER AG (DE) 1993-10-06 EP disclosed
US-5225428-A Hypotensive and anti-atherosclerotic agents BAYER AKTIENGESELLSCHAFT (DE) 1993-07-06 US disclosed
EP-0535465-A1 Cyclic substituted imidazolylpropen acid derivatives as angiotensin II antagonists BAYER AG (DE) 1993-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125473-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885HPGD 2124/4885MEN1 493/4885
US-20090312326-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885HPGD 2124/4885MEN1 493/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ALDH1A1 4236/4885HPGD 905/4885MEN1 1514/4885
US-20070167506-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885HPGD 2124/4885MEN1 493/4885
US-20080119536-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885HPGD 2124/4885MEN1 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.